Zymeworks Inc reports results for the quarter ended March 31 - Earnings Summary

Zymeworks

08/05/2025 23:28

Zymeworks Inc ZYME.OQ reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -42 cents.  The mean expectation of eight analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -51 cents to -15 cents per share.

Revenue rose 170.3% to $27.11 million from a year ago; analysts expected $20.65 million.

Zymeworks Inc's reported EPS for the quarter was a loss of 30 cents​.

The company reported a quarterly loss of $22.64 million.

Zymeworks Inc shares had fallen by 4.8% this quarter and lost 22.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 12.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Zymeworks Inc is $19.50

This summary was machine generated from LSEG data May 8 at 10:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.41
-0.30
Beat
Dec. 31 2024
-0.10
-0.31
Missed
Sep. 30 2024
-0.40
-0.39
Beat
Jun. 30 2024
-0.32
-0.27
Beat